Bristol Myers Squibb’s Breyanzi shows promise in B-cell malignancy clinical trials
"Bristol Myers Squibb’s Breyanzi shows promise in B-cell malignancy clinical trials" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
FDA Expands Approval For Bristol Myers Squibb's Breyanzi, Making CAR T Cell Therapy Available For Broadest Range Of B-Cell Malignancies
Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior lines of systemic therapy.
Bristol Myers Squibb’s Breyanzi gains FDA approval for lymphoma
Bristol Myers Squibb (BMS) has received FDA approval for Breyanzi to treat adults with relapsed or refractory mantle cell lymphoma.
Bristol Myers' 3 Breyanzi Trials Show Consistent Benefit Across B-Cell Malignancies
(RTTNews) - Bristol-Myers Squibb Co. (BMY), Monday announced that data from its three studies and a three-year follow-up from the Phase 3 TRANSFORM trial of Breyanzi showed consistent clinical benefits. BMY considers Breyanzi as a second-line treatment in patients with relapsed or refractory large B-cell lymphoma.
Bristol Myers Squibb inks clinical trial pact with I-Mab
Cancer drug developer I-Mab (IMAB) on Wednesday announced a clinical trial and supply agreement with Bristol Myers Squibb (NYSE:BMY) to study its bispecific antibody givastomig developed with Korean biotech ABL Bio.
Zacks.com on MSN4d
Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo (Revised)
Bristol Myers Squibb BMY announced data from three studies evaluating CD19-directed CAR T cell therapy Breyanzi (liso-cel) at ...
FiercePharma10d
Bristol Myers secures another FDA go-ahead for Breyanzi, this time in mantle cell lymphoma
In the years since gaining an initial FDA approval for Breyanzi, Bristol Myers Squibb has worked hard to expand the reach ...
Pharm Exec9d
FDA Approves Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma
Breyanzi, a CD19-directed CAR T-cell therapy, granted fourth FDA approval to treat a distinct subtype of non-Hodgkin lymphoma ...
US FDA expands use of Bristol's cell therapy to treat rare blood cancer
Bristol Myers Squibb said on Thursday the US FDA had allowed expanded use of its cell therapy for an aggressive and rare type ...
Monthly Prescribing Reference10d
Breyanzi Approved for Relapsed or Refractory Mantle Cell Lymphoma
The Food and Drug Administration (FDA) has approved Breyanzi (lisocabtagene maraleucel; liso-cel) for the treatment of adults with relapsed or refractory mantle cell lymphoma (MCL) who have received ...
Yahoo Finance5d
Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo
Bristol Myers Squibb BMY announced data from three studies evaluating CD19-directed CAR T cell therapy Breyanzi (liso-cel) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
Nasdaq5d
Bristol Myers' 3 Breyanzi Trials Show Consistent Benefit Across B-Cell Malignancies
(RTTNews) - Bristol-Myers Squibb Co. (BMY), Monday announced that data from its three studies and a three-year follow-up from the Phase 3 TRANSFORM trial of Breyanzi showed consistent clinical ...